Novartis | NVS - Ebitda


Novartis reported $5.84B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.23B 272M Sep/2025
Bausch Health Companies USD 986M 74M Sep/2025
Biogen USD 573.2M 253.7M Dec/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Glaxosmithkline GBP 4.75B 1.52B Sep/2025
J&J USD 9.52B 389M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Novartis USD 4.77B 1.11B Dec/2025
Novartis USD 5.84B 235M Sep/2025
Pacira USD 38.71M 10.65M Dec/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 4.84B 2.95B Sep/2025
Sanofi EUR 5.66B 3.77B Sep/2025
Supernus Pharmaceuticals USD 48.5M 6.6M Dec/2025
Zoetis USD 1.04B 87M Sep/2025